LMLena Marth

Lena Marth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lena Marth has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome

    by Olivia Wagemann, Georg S. Nuebling, Katja Sandkühler, Elisabeth Wlasich, Sandra V. Loosli, Catharina Prix, Anna Christina Stockbauer, Lena Marth, Anabel Forte, Jonathan Vöglein, et al.

    Background and ObjectivesAdults with Down syndrome (DS) have an increased risk of developing early Alzheimer disease. While our previous cross-sectional study investigated the blood proteome in the...

  • Open Access

    Frailty in Adults With Down Syndrome: Cognitive, Functional and Biomarker Associations

    by Georg Nübling, Lena Marth, Katja Sandkühler, Anna Stockbauer, Elisabeth Wlasich, Alexander Jäck, Olivia Wagemann, Julia Kustermann, Steffen Halbgebauer, Hayrettin Tumani, et al.

    Background: Down syndrome (DS) entails widespread age‐related functional decline affecting multiple organ systems, including genetically determined early‐onset Alzheimer disease (DSAD), resulting in an increased vulnerability to frailty early in life. We investigated the relationship between frailty, cognition and intellectual disability (ID) in adults with DS and explored biomarkers associated with frailty. Methods: This cross‐sectional study investigated 148 consecutive patients at a DSAD outpatient clinic. We applied correlation analyses and hierarchical linear models to determine associations of the Frailty Index for people with Intellectual Disabilities—short form (ID‐FI SF ) with measures of cognition (Cambridge cognitive assessment, CAMCOG‐DS), adaptive function (short adaptive behaviour scale, SABS), motor function (SPES/SCOPA), a screening tool (dementia screening questionnaire in individuals with intellectual disabilities, DSQIID‐G) for dementia‐related change in ADL (activities of daily living) performance, and ID severity (DSM‐5). Patients were stratified as cognitively healthy, DS‐MCI, DSAD dementia, secondary cognitive decline (CD) or CD of unknown cause. Exploratory analyses included blood biomarkers, bioimpedance measurements and indirect calorimetry. Results: Both baseline ID severity ( β = 0.093, p = 0.014) and cognitive performance (CAMCOG‐DS, β = −0.0033, p < 0.001) were independently associated with ID‐FI SF scores. Acquired cognitive decline was associated with (pre)frailty irrespective of aetiology. After adjustment for ID severity and cognition, ID‐FI SF scores were associated with adaptive function (SABS: β = −0.0033, p < 0.001), motor function (SPES‐SCOPA: β = 0.015, p < 0.001), change in ADL performance (DSQIID‐G: β = 0.0061, p < 0.001) and medication burden ( β = 0.016, p < 0.001). Exploratory biomarker analyses identified associations with ID‐FI SF scores for markers of neurodegeneration, inflammation, body composition, cardiac function and cellular stress signalling. Conclusions: Frailty in DS is associated with both ID severity and acquired cognitive decline. Future studies should determine whether severe baseline ID increases susceptibility to frailty or primarily influences frailty measurement through lower baseline functional abilities, potentially necessitating ID‐adapted frailty thresholds. Biomarker associations further support a multifactorial model of frailty involving neurodegeneration, inflammation and sarcopenia‐related processes.

  • Open Access

    Demenz mit Lewy-Körperchen

    by Lena Marth, Adèlina Lund, Günter Höglinger, Johannes Levin

    Zusammenfassung: Die Demenz mit Lewy-Körperchen (DLB) ist nach der Alzheimer-Demenz die zweithäufigste neurodegenerative Demenzform und zählt zu den atypischen Parkinson-Syndromen. Sie ist charakterisiert durch kognitive Fluktuationen, visuelle Halluzinationen, eine REM-Schlaf-Verhaltensstörung und Parkinson-Symptome. Typischerweise treten die kognitiven Einbußen vor oder bis maximal ein Jahr nach Beginn der motorischen Symptomatik auf („Einjahreskriterium“). Neuropathologisch liegt eine α-Synukleinopathie mit Lewy-Körperchen in Neuronen vor, häufig begleitet von Kopathologien. Die Diagnosestellung erfolgt klinisch nach den McKeith-Kriterien unter Einbeziehung z.B. bildgebender Biomarker. Therapeutisch stehen symptomorientierte Ansätze im Vordergrund. Krankheitsmodifizierende Therapien stehen bislang nicht zur Verfügung, werden jedoch in Therapiestudien erprobt. Die Entwicklung biologisch definierter Diagnosekriterien und molekularer Biomarker ist zentral für zukünftige Therapiestudien.


  • Characterization of a novel homozygous CTSD variant causing adult-onset neuronal ceroid lipofuscinosis type 10: a case report

    by Lena Marth, André R. A. Marques, Soheyl Noachtar, Jan Rémi, Endy Weidinger, Katharina Ernst, Florian Schöberl, Johannes S. Gnörich, Matthias Brendel, Saskia Biskup, et al.

  • Open Access

    Privacy-Preserving Mobile Face Tracking for Assessing Empathic Facial Reactivity: Cross-Sectional Study in Healthy Adults (Preprint)

    by Cem Doğdu, Leon Nissen, Luca Kleineidam, Carolin Miklitz, Johanna Knöferle, Klaus Fliessbach, Lena Marth, Johannes Levin, Elisabeth Kasper, Andreas Hermann, et al.

  • Open Access

    Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia

    by Lena Marth, Francisco J. Martinez-Murcia, Juan-Manuel Górriz-Sáez, Jannis Denecke, Michael Ewers, Catharina Prix, Anna Christina Stockbauer, Alexander Maximilian Bernhardt, Olivia Wagemann, Elisabeth Wlasich, et al.

    Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217], p < 0.003), sex (1.376 [0.666-2.087], p < 0.001), and the interaction between the nonfluent variant of PPA and sex (-1.940 [-3.242 to -0.638], p = 0.004) showed a significant effect on the active behavioral phenotype, with symptom severity increasing over time and being most pronounced in men with bvFTD. Patients with bvFTD exhibited more severe passive behavioral symptoms compared with any other diagnostic group. For the affective phenotype, a significant interaction between time and sex (0.063 [0.010-0.117], p = 0.021) indicated a progressive increase in symptom severity in men over time. Furthermore, we found robust neuroanatomical correlations of passive behavioral symptoms with subcortical and bilateral frontal and cingulate cortical atrophy. Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.